Our Science
BirchBioMed is at the forefront of biopharmaceutical innovation, focusing on the development of advanced treatments for fibrosis and certain autoimmune disorders. Our science centers around the therapeutic potential of Kynurenic Acid (KynA), also known as ‘FS2’, a compound with notable antifibrogenic properties capable of enhancing extracellular matrix (ECM) remodeling.
At BirchBioMed, we leverage KynA across a range of applications: topical creams, systemic administration, and a pioneering approach, known as AI-001, that combines a one-time delivery of APCs with systemic KynA administration to produce a synergistic effect in the treatment of certain autoimmune conditions.
Our multidisciplinary strategy embodies the latest in scientific research to address complex medical challenges. The active use of KynA in our treatments targets the foundational aspects of fibrosis and, in combination with APCs, produces synergistic immune regulation in some clinical subsets of autoimmune disorders, offering new hope in managing severe conditions. This innovative approach reflects our commitment to pushing the boundaries of medical science, relentlessly exploring new therapeutic pathways and advanced treatment modalities to improve patient outcomes.
Kynurenic Acid MoA
KynA is a promising antifibrogenic candidate, targeting the fundamental mechanisms driving fibrosis, such as fibroblast proliferation, ECM accumulation, and cellular migration. It has demonstrated potential in improving healing outcomes for patients suffering from atrophic, hypertrophic and keloidal scarring—conditions characterized by excessive and disorganized scar tissue.
Immune Cell Therapy and KynA
AI-001 is a groundbreaking first-generation candidate for autoimmune therapy, uniquely designed to involve a single, one-time injection of APCs in conjunction with daily systemic administration of kynurenic acid. This innovative approach elicited a strong, synergistic immunomodulating effect that significantly reduced autoimmune diabetes onset in the non-obese diabetic mouse model (type 1 diabetes model), reversing hyperglycemia onset in 75% of the tested sample. AI-001 combination therapy also prevented alopecia areata onset and progression in a separate autoimmune mouse model.
University of British Columbia
As a University of British Columbia (“UBC”) spin-off, BirchBioMed has taken on the heavy challenge of developing FS2 and AI-001 in major therapeutic indications to be made available to millions of patients.
